The Science Behind Amatista Biotech
FAQs on CAR-T and the Amatista Universal Switch
What is CAR-T cell therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of adoptive cell therapy in which a patient’s T cells are collected, genetically engineered to recognize specific disease-associated antigens, expanded ex vivo, and reinfused into the patient. Once administered, CAR-T cells can selectively identify and kill target cells, leading to transformative clinical responses in certain blood cancers. However, once infused, conventional CAR-T cells cannot be easily controlled, which contributes to safety risks and limits broader use.
What is the kinase-switch CAR-T platform?
The kinase-switch CAR-T platform is a controllable CAR-T cell technology that allows clinicians to reversibly turn CAR-T cell activity ON or OFF using a small-molecule drug. It is based on a computationally engineered tyrosine kinase that is selectively inhibited by the FDA-approved drug erlotinib, enabling real-time control of CAR-T cell function after infusion.
Why is controllability important in CAR-T cell therapy?
While CAR-T therapies can be highly effective, uncontrolled T-cell activation can lead to serious toxicities such as cytokine release syndrome (CRS) and neurotoxicity. Current safety approaches, such as suicide switches, permanently eliminate CAR-T cells. The kinase-switch provides a reversible and dose-dependent way to manage toxicity without destroying therapeutic cells.
How does the kinase-switch work?
A tyrosine kinase that is essential for T-cell activation is either replaced or functionally integrated with a computationally modified kinase variant. This engineered kinase functions normally in the absence of erlotinib (ON state). When erlotinib is administered, the kinase is inhibited, temporarily halting CAR-T cell activation and effector functions (OFF state). Removing the drug restores activity.
Is the control reversible?
Yes. Multiple in vitro and in vivo studies demonstrate that CAR-T cell functions such as cytokine secretion and tumor cell killing are fully restored after erlotinib withdrawal, with no loss of potency.
What drug is used to control the switch?
The platform uses erlotinib, an FDA-approved tyrosine kinase inhibitor with well-characterized pharmacology and clinical use. This makes the approach highly translatable to the clinic.
How fast does the switch act?
The kinase-switch acts rapidly (3-4 hours in vivo). CAR-T cell cytokine production and cytotoxic activity are effectively blocked shortly after erlotinib administration and resume once the drug is cleared or withdrawn.
Does the kinase-switch affect only engineered CAR-T cells?
Yes. The engineered kinase is selectively sensitive to erlotinib, allowing targeted control of kinase-switch CAR-T cells without broadly suppressing the patient’s immune system, unlike non-specific kinase inhibitors such as dasatinib.
Can the kinase-switch be used with existing CAR designs?
Yes. The kinase-switch can be:
- Used as a universal safety switch alongside conventional second-generation (2G) CARs.
- Or directly integrated into the CAR architecture by replacing the CD3ζ signaling domain.
What CAR targets are compatible with the platform?
The platform is broadly adaptable and has been validated with CARs targeting PSMA, CD19, BCMA, and EpCAM. The scFv can be readily exchanged to target additional tumor antigens.
Is the kinase-switch compatible with different costimulatory domains?
Yes. The design is compatible with commonly used costimulatory domains such as CD28 and 4-1BB.
Can the platform be used in solid tumors?
Yes. Preclinical in vivo studies demonstrate controllable tumor growth in solid tumor models, including prostate cancer (PSMA). The switch allows CAR-T cell activity to be paused in response to toxicity and reactivated afterward.
Does transient shut-off affect CAR-T cell persistence?
Transient resting of CAR-T cells may actually enhance persistence and long-term function, as suggested by prior studies using pharmacological resting approaches.
Is this platform compatible with armored CAR-T cells?
Yes. The kinase-switch is compatible with armored CAR-T constructs, including those engineered to inducibly secrete cytokines such as IL-18.
Can the kinase-switch be used in allogeneic (off-the-shelf) CAR-T therapies?
Yes. The platform is compatible with allogeneic T-cell systems and can support universal donor CAR-T approaches.
How is the kinase-switch introduced into T cells?
The engineered kinase can be introduced via viral transduction or gene knock-in approaches. In some CAR designs, knockout of the endogenous kinase is not required.
What are the key advantages over suicide switches?
- Reversible control rather than permanent cell elimination
- Dose-dependent tuning of CAR-T activity
- Preservation of therapeutic cells
- Improved safety and therapeutic window
What evidence supports the platform’s effectiveness?
Our preclinical data show:
- Complete and reversible suppression of cytokine secretion (e.g., IFN-γ, IL-2, Granzyme B)
- Reversible inhibition of tumor cell killing
- In vivo control of CAR-T-mediated tumor suppression upon erlotinib administration
Is the technology protected by intellectual property?
Yes. The kinase-switch design is proprietary and supported by computational protein engineering and IP protection.
What are the next development milestones?
Planned activities over the next 12–24 months include:
- Expanded in vivo efficacy and safety studies in solid and liquid tumor models
- Evaluation of additional kinase inhibitors predicted by computational modeling
- Publication of a proof-of-concept manuscript
- Development of next-generation armored kinase-switch CAR-T cells - Advancement toward IND-enabling studies
Who is this technology intended for?
The kinase-switch CAR-T platform is designed for clinicians, patients, and industry partners seeking safer, more controllable, and adaptable next-generation CAR-T cell therapies.
Why is Amatista well-positioned to win?
Amatista Biotech Car-T Universal Switch technology combines:
- A highly differentiated, clinically feasible control mechanism
- Use of an FDA-approved small molecule
- Broad platform applicability
- Strong translational focus and IP protection
Together, these elements position Amatista as a next-generation CAR-T platform company addressing one of the field’s most critical unmet needs.